Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Jaguar Health Inc. | Mytesi (crofelemer) - (HALT-D) | Cancer related diarrhea (CRD) | Phase 3 | Trial Completed | Oral | Oncology |
| Jaguar Health Inc. | Mytesi (crofelemer) - (HALT-D) | Cancer related diarrhea (CRD) | Phase 3 | Trial Completed | Oral | Oncology |
| Jaguar Health Inc. | Mytesi (crofelemer) - (OnTarget) | Cancer Therapy-Related Diarrhea | Phase 3 | Trial Completed | oral | Oncology |
| Jaguar Health Inc. | Mytesi (crofelemer) - (HALT-D) | Cancer related diarrhea (CRD) | Phase 3 | Trial Completed | Oral | Oncology |
| Jaguar Health Inc. | Crofelemer | Short Bowel Syndrome with Intestinal Failure (SBS-IF) | Phase 2 | Data Released | Oral | Gastroenterology |
| Jaguar Health Inc. | Crofelemer | Microvillus Inclusion Disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) | Phase 2 | Data Released | Oral | Gastroenterology |
| Jaguar Health Inc. | Mytesi (crofelemer) | Inflammatory bowel disease (IBS-D) | Phase 2 | Data Released | Oral | Gastroenterology |
| Jazz Pharmaceuticals plc | Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) | First-line HER2-positive gastroesophageal adenocarcinoma (GEA) | Phase 3 | Data Released | Intravenous infusion | Oncology |
